摘要
目的探讨米非司酮及内美通用于重度盆腔子宫内膜异位症穴内异症雪腹腔镜术后辅助药物治疗的疗效及安全性。方法回顾分析了156例重度盆腔子宫内异症患者腹腔镜术后随访资料,比较术后应用米非司酮、内美通及未用药组的复发率和副反应发生率。结果米非司酮组、内美通组复发率分别为13郾6%、11郾1%,低于未用药组34郾6%穴P<0郾05,P<0郾05雪。米非司酮组副反应发生率为11郾9%,显著低于内美通组44郾4%穴P<0郾05雪。结论米非司酮、内美通用于盆腔子宫内膜异症腹腔镜术后的治疗,能显著地降低内异症的复发率,提高妊娠率,且米非司酮副反应较少。
OBJECTIVE To investigate the effects and safety of mifepristone and gestrinone for treating for postoperative patients with se-vere pelvic and ometriosis.METHODS 156 severe pelvic endometriosis cases were analyzed retrospectively.Of the cases,59 cases were administered mifepristone,45 cases were administered gestrinone and other 52 cases had not taken any hormone.Recurrence rate,side effect rates were compared among these groups.RESULTS The recurrence rate of mifepristone group and gestrinone group were 13.6% and 11.1%,respectively,which was significantly lower than that of control group (P<0.05,P<0.05).The side effect rate of mifepristone group was 11.9%,which was significantly lower than that of gestrinone group(44.4%)(P<0.05)CONCLUSIONS The treatment of mifepristone and gestrinone treatment on postoperative patients with pelvic endometriosis,can significantiy decreased the re-currence rate of pelvic enaometriosisand elevate pregnancy rate.Mifepristone has less side effects than that of gestrinone.
出处
《中国初级卫生保健》
2005年第1期86-87,共2页
Chinese Primary Health Care
